ZVXI - Zevex International - Traumzahlen veröffentlicht heute +100% - 500 Beiträge pro Seite

[Midi2000]

gestern nachbörslich Traumzahlen:

ZEVEX Reports Record Net Income and Earnings Per Share of $0.22 on Revenue Gain of 52% for Third Quarter 2005

ZEVEX International Inc. (Nasdaq: ZVXI) reported record financial results for the three and nine months ending Sept. 30, 2005.

Net income for the third quarter ending Sept. 30, 2005, was a record $785,483, or $0.22 per share, compared with a net loss of $294,721, or ($0.09) per share, for the same period of 2004. For the nine-month period ending Sept. 30, 2005, net income was a record $999,104, or $0.28 per share, compared with $106,952, or $0.03 per share, for the same period of 2004.

Revenue for the third quarter ending Sept. 30, 2005, increased 52 percent to $8.1 million, compared with $5.3 million for the third quarter of 2004. For the nine-month period ending Sept. 30, 2005, revenue grew by 18 percent to $20.9 million, compared with $17.8 million for the same period of 2004.

ZEVEX CEO and President David McNally said, "Sales were very strong in both of our divisions during the third quarter. Our Applied Technology division produced revenue of $3.4 million, a 44 percent gain over third quarter 2004 revenue of $2.3 million. Applied Technology division sales were substantially higher this quarter due to strong demand from two of our largest customers.

"In addition, our Therapeutics division produced revenue of $4.7 million, a 59 percent gain over third quarter 2004 revenue of $3.0 million. The international revenue from our Therapeutics division increased more than sixfold over last year`s third quarter, primarily based upon sales to Numico, our exclusive distributor for a private-label version of our newest, most advanced enteral feeding pump, the EnteraLite(R) Infinity(R), that provides patients in hospitals, nursing homes, or at home with the lightest, most accurate, and longest lasting, battery-operated pump available in Europe. Also, growth in our domestic ambulatory pump and disposable set sales led to a 14 percent increase in revenue from our Therapeutics division during this year`s third quarter," concluded McNally. McNally further stated that the company has added a second production shift in order to support forecasted demand for the company`s products.

Gross profit for the third quarter increased to 38 percent, compared with 34 percent in the same quarter of 2004, primarily due to the product mix delivered during the quarter. Operating expenses continued to decline as a percent of sales to 28 percent for the third quarter of 2005, compared with 40 percent for the same quarter of 2004. Selling, general and administrative expenses were 24 percent of sales for the third quarter of 2005, compared with 32 percent for the same quarter of 2004. Research and development expenses for the third quarter of 2005 were 4 percent of sales, compared with 8 percent of sales for the same quarter of 2004. Operating income for the third quarter of 2005 was 10 percent of sales, compared with a loss for the same quarter of 2004.

For both the nine-month periods ended Sept. 30, 2005 and 2004, gross profit was 37 percent. Operating expenses for the first nine months of 2005 were 32 percent of sales, compared with 36 percent of sales for the same period of 2004. Selling, general and administrative expenses were 27 percent of sales for the nine-month period of 2005, compared with 30 percent for the same period of 2004. R&D expenditures were 4 percent of sales for the first nine months of 2005, compared with 6 percent of sales for the same period of 2004. For the nine-month period ended Sept. 30, 2005, operating income was 5 percent of sales, compared with 1 percent of sales for the same period of 2004.

McNally added, "We are very encouraged by this quarter`s performance. The reductions in operating expenses expressed as a percentage of sales for the third quarter and first nine months of 2005 compared to the same periods of 2004 indicate that we have been able to generate more sales without proportionally increasing overhead expenses. This operating leverage is a tribute to our management team and all our employees who are exercising budget control while driving sales growth."

CONFERENCE CALL

ZEVEX International Inc. invites all those interested to join the ZEVEX management team for its earnings conference call for the third quarter ended Sept. 30, 2005. The call will be held Tuesday, Nov. 1, 2005, at 4:30 p.m. EDT (3:30 p.m. Central, 2:30 p.m. Mountain, 1:30 p.m. Pacific). The telephone numbers for the call are as follows:

Domestic: 800-257-6566

International: 303-262-2052

A live webcast and a rebroadcast of the conference call will be available on the company`s Web site at www.zevex.com and www.streetevents.com. To listen to the live broadcast, please enter the site 10-15 minutes prior to the call in order to download any necessary software, and then click on the "Webcast" icon on the ZEVEX home page to access the call. The webcast will be archived on both sites. There is no other replay access to the call.

ABOUT ZEVEX

ZEVEX International Inc. (www.zevex.com), founded in 1986, is a diversified medical device company committed to creating products that transform life with patented and proprietary medical device technologies -- from sensors and surgical tools to medical electronic systems. For more information concerning ZEVEX and its products, please visit the ZEVEX Web site at the following link: www.zevex.com.

Forward-Looking Statements

Statements made in this press release, including those relating to forecasted demand, anticipated revenue and profit growth and other statements regarding future performance, are forward looking and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause actual results to differ materially from those set forth in these statements. Among these, the company`s efforts to continue to improve its sales and margins in its core businesses may not be effective, or such efforts could be more difficult or expensive than the company currently anticipates. Further, demand from the company`s largest customers could fluctuate, possibly impacting revenue on a quarterly or annual basis. In addition to the foregoing, the economic, competitive, governmental, technological and other factors identified in the company`s filings with the Securities and Exchange Commission, including the Form 10-K for the year ended Dec. 31, 2004, may cause actual results or events to differ materially from those described in the forward-looking statements in this press release.

ZEVEX INTERNATIONAL INC.
CONSOLIDATED INCOME STATEMENT

Three Months Ended Nine Months Ended
Sept. 30, Sept. 30,
2005 2004 2005 2004
(unaudited)(unaudited)(unaudited) (unaudited)
Revenue:
Product sales $7,985,249 $5,187,253 $20,512,430 $17,180,510
Engineering services 151,974 152,153 406,610 591,597
---------- ---------- ----------- ------------
Total revenue 8,137,223 5,339,406 20,919,040 17,772,107

Cost of sales 5,056,861 3,517,818 13,183,688 11,193,467
---------- ---------- ----------- ------------
Gross profit 3,080,362 1,821,588 7,735,352 6,578,640

Operating expenses:
Selling, general and
administrative 1,945,200 1,707,321 5,746,869 5,408,745
Research and
development 330,242 427,711 895,870 993,354
---------- ---------- ----------- ------------
Total operating expenses 2,275,442 2,135,032 6,642,739 6,402,099

Operating income (loss) 804,920 (313,444) 1,092,613 176,541
Other income (expense):
Interest and other
income 12,337 10,120 28,892 14,976
Interest expense (31,774) (25,254) (119,766) (114,807)
---------- ---------- ----------- ------------

Income (loss) before
income taxes 785,483 (328,578) 1,001,739 76,710

Benefit (provision) for
income taxes -- 33,857 (2,635) 30,242
---------- ---------- ----------- ------------

Net income (loss) $785,483 ($294,721) $999,104 $106,952
========== ========== =========== ============

Basic net income (loss)
per share $0.23 ($0.09) $0.29 $0.03
========== ========== =========== ============

Weighted average shares
outstanding 3,407,290 3,400,964 3,404,549 3,400,964
========== ========== =========== ============

Diluted net income
(loss) per share $0.22 ($0.09) $0.28 $0.03
========== ========== =========== ============

Diluted weighted average
shares outstanding 3,575,475 3,400,964 3,531,890 3,473,602
========== ========== =========== ============


ZEVEX INTERNATIONAL INC.
CONSOLIDATED BALANCE SHEET

Sept. 30, Dec. 31,
2005 2004
ASSETS (unaudited)

Current assets
Cash and cash equivalents $613,362 $212,859
Designated cash for sinking fund payment
on industrial development bond 71,897 96,042
Accounts receivable, net of allowances
for doubtful accounts of $158,000 and
$192,000 5,543,932 3,563,436
Other receivable -- 35,500
Inventories 4,285,552 4,584,755
Marketable securities 28,800 29,250
Prepaid expenses and other current assets 68,763 149,690
----------- -----------
Total current assets 10,612,306 8,671,532
Property and equipment, net 4,605,962 4,345,942
Patents, trademarks and other intangibles,
net 354,122 335,244
Goodwill, net 4,048,264 4,048,264
----------- ------------
Total assets $19,620,654 $17,400,982
=========== ============
LIABILITIES AND STOCKHOLDERS` EQUITY

Current liabilities
Accounts payable $2,338,158 $1,949,618
Other accrued liabilities 859,078 606,734
Deferred revenue 83,332 --
Bank line of credit 610,536 --
Income taxes payable 2,005 2,005
Current portion of industrial development
bond 100,000 100,000
Current portion of other long-term debt 55,460 53,246
----------- ------------
Total current liabilities 4,048,569 2,711,603

Industrial development bond 1,100,000 1,200,000
Other long-term debt 724,486 766,362

Stockholders` equity
Common stock; $.001 par value, 10,000,000
authorized shares, 3,446,850 issued and
3,407,617 outstanding at Sept. 30, 2005,
and 3,440,197 issued and 3,400,964
outstanding at Dec. 31, 2004 3,447 3,440
Additional paid-in capital 16,316,373 16,290,452
Unrealized gain on marketable securities (18,975) (18,525)
Treasury stock; 39,233 shares (at cost)
at Sept. 30, 2005, and Dec. 31, 2004 (89,422) (89,422)
Accumulated deficit (2,463,824) (3,462,928)
----------- ------------
Total stockholders` equity 13,747,599 12,723,017
----------- ------------

Total liabilities and stockholders` equity $19,620,654 $17,400,982
=========== ============

ZEVEX International Inc., Salt Lake City
Nancy E. Schultz, 801-264-1001, ext. 203
[e-mail]


Source: Business Wire (November 1, 2005 - 4:02 PM EST)

News by QuoteMedia
www.quotemedia.com



Amis flippen vollkommen aus, heute teilweise fast +100%

[Midi2000]

Das Gap heute ist natürlich megabrutal. Aber die Umsätze heute dahinter sind ebenfalls krass. Die Aktie ist aus dem Dornröschenschlaf erwacht.

[Midi2000]

Marktkapitalisierung momentan ca 33Mio Dollar. Es gibt 3,41Mio Aktien von dem Teil. Heute nach nicht einmal 90 Minuten 1,6Mio Aktien gehandelt. Ich denke, daß ist heute erst der Anfang.

[Midi2000]

Das interessante an so einem Gap. Es konnte kaum einer vorher extrem billiger als zur hutigen Eröffnung von 8,45 Dollar einsteigen. Gestriger Schlußkurs 5,39Dollar.

Jetzt befindet sich der Wert um die 10Dollar.

Was gestern Abend bei dieser Telefonkonferent heraus gekommen is, weiss ich nicht. So schlecht kann sie aber wohl kaum verlaufen sein.

[Midi2000]

Also zu 10Dollar liegt natürlich immer eine Menge im ASK. Ist schliesslich eine glatte runde Zahl. Im Hoch ganz kurz mal bei 10,60. Aber nun wird das ASK immer mehr nachgefüllt.

Ich rechne aber trotzdem heute zum Schluß mit einem guten Endspurt und sehe Kurse in Richtung von 11-12 Dollar wie schon gesagt. Und auch danach, bleibt der Wert interessant.

[Midi2000]

Mh das Interesse hier scheint ja nicht gigantisch zu sein.

[Midi2000]

So die 10 Dollar sollten geschafft sein. Jetzt geht es beständig dem Tageshoch von 10,60 Dollar entgegen.

[Buddah]

Schöner Chart!

[Pennystock777]

ZEVEX International Announces 3-for-2 Stock Split
ZEVEX International Inc. (NASDAQ: ZVXI), developer and manufacturer of high-quality, high-value medical products, announced today that its board of directors has approved a 3-for-2 stock split on all shares of its outstanding common stock, that will be effected in the form of a 50% stock dividend. The dividend will entitle all stockholders on record, as of the close of business on May 4, 2006, to receive one additional share of common stock for every two shares of common stock held at such time. The additional shares will be distributed to all stockholders on or about May 19, 2006. Currently, the company has approximately 3.6 million shares of common stock outstanding. After giving effect to the stock split, the company will have approximately 5.5 million shares of common stock outstanding. The board of directors believes the stock split reflects its confidence in the outlook for ZEVEX, and that the increase in outstanding shares will enhance the trading of the company's stock.

About ZEVEX

ZEVEX International Inc. (www.zevex.com), founded in 1986, is a diversified medical device company committed to creating products that transform life with patented and proprietary medical device technologies -- from sensors and surgical tools, to medical electronic systems.


ZEVEX International Inc., Salt Lake City
Phill McStotts, 801-264-1001, ext. 203
Fax: [phone]
E-mail: [e-mail]

[Pennystock777]

ZEVEX Reports Record Net Income and Earnings Per Share of $0.36 on Revenue Growth of 77% for First Quarter 2006
ZEVEX International Inc. (NASDAQ: ZVXI) reported financial results for the three months ended March 31, 2006.

Revenue for the first quarter of 2006 increased 77% to $10.6 million, compared with revenue of $6.0 million for the first quarter of 2005. Net income was a record $1.5 million, or $0.36 per share, compared with net income of $45,000, or $0.01 per share, for the first quarter of 2005. Notably, net income for the first quarter of 2006 reflects a $95,000 charge relating to outstanding stock options, as newly required under the accounting rules.

Total revenue from the company's Therapeutics division for the first quarter of 2006 increased by 140% to $6.9 million, compared with $2.9 million for the first quarter of 2005. Specifically, sales of domestic enteral feeding pumps and disposable delivery sets increased by 22%, or $531,000, compared with last year's first quarter, while international sales of pumps and sets in the same period increased by $3.5 million, or 841%. The increase in these international sales was due primarily to increased revenue from Nutricia Clinical, a division of Royal Numico and the company's largest strategic international distribution partner. Sales from the company's Therapeutics division in the first quarter of 2006 accounted for 65% of the company's total revenue.

Total revenue from the company's Applied Technology division for the first quarter of 2006 increased by 19% to $3.7 million, compared with $3.1 million for the first quarter of 2005. Revenue from sensors and handpieces grew by $732,000, or 33%, over the first quarter of 2005, while revenue from medical systems declined by $278,000, or 34%. Revenue from engineering services increased by 164%, or $143,000, over the first quarter of 2005. Sales from the company's Applied Technology division in the first quarter of 2006 accounted for 35% of the company's total revenue.

The increase in net income for the first quarter of 2006 was due primarily to the substantial increase in revenue and the resulting increase in gross profit. In addition, in the first quarter, the company recorded a tax benefit of $446,000, which was related to the partial reversal of a valuation allowance from a prior period. Operating expenses increased to approximately $2.7 million during the first quarter of 2006, compared with $2.1 million for the first quarter of 2005. This increase in operating expenses was primarily due to increased investments in sales and marketing, and to increased general and administrative expenses, including recruiting expenses, personnel and insurance costs, legal fees, stock option expenses and bonus incentive accruals.

David J. McNally, ZEVEX's president and CEO, said, "We are delighted to report another quarter of record earnings, as well as record revenue for the first quarter of 2006. Both our Applied Technology and Therapeutics divisions are performing well. Our largest Applied Technology customers contributed significantly to the 33% growth in the sales of our surgical handpieces and sensors. Our domestic Therapeutics sales team drove growth of 22%, based upon the strength of our EnteraLite(R) Infinity(R) and EnteraLite(R) portable feeding pumps. International sales revenue in our Therapeutics division exceeded our expectations, based upon the accelerated introduction of Flocare(R) Infinity(R) portable feeding pumps by Nutricia Clinical in Europe. This was also the first full quarter that we recognized service revenue associated with the servicing of these pumps for Nutricia Clinical, which added over $800,000 in new service revenue for the quarter.

"Our current outlook for 2006 remains positive," continued McNally. "Our Applied Technology customers are forecasting continuing demand for our products at a level that is consistent with the level that we achieved in the first quarter of 2006. Our domestic Therapeutics sales force has been performing well, building upon last year's successful market introduction of our EnteraLite Infinity product line. Internationally, we expect that our business with Nutricia Clinical -- both our sales revenue and our service revenue -- will be strong during the next three quarters. During the first quarter of 2006, we achieved $3.5 million in revenue from our pump shipments and service to Nutricia Clinical. As a result, we are increasing our Nutricia forecast from $8 million to $10 million for the full year 2006. Based upon our current outlook, we are raising our projection for overall year-over-year revenue growth in 2006 to 25%.

"During the first quarter, we achieved record income," continued McNally. "I would like to remind investors that we enjoyed a substantial tax benefit of $446,000 during the first quarter, which more than offset a stock option expense of approximately $95,000 for the quarter under the new accounting rules. Also, significantly, in the second quarter of 2006, we successfully defended our patent rights for which we received a settlement payment of $1,000,000, as we have described in our SEC Form 8-K, which we filed earlier this month. This $1,000,000 payment will be reflected as other income, offset by less than $100,000 in legal fees, in our second quarter financials."


--------------------------------------------------------------------------------

ZEVEX INTERNATIONAL INC.
CONSOLIDATED STATEMENTS OF OPERATIONS

Three months ended March 31,
2006 2005
(unaudited) (unaudited)
----------------------------
Revenue:
Product sales $10,330,555 $5,881,454
Engineering services 262,602 102,710
------------- ------------
Total revenue 10,593,157 5,984,164

Cost of sales 6,844,472 3,797,659
------------- ------------
Gross profit 3,748,685 2,186,505

Operating expenses:
General and administrative 1,365,267 974,679
Selling and marketing 1,026,616 815,700
Research and development 309,111 321,656
------------- ------------
Total operating expenses 2,700,994 2,112,035

Operating income 1,047,691 74,470

Other income (expense):
Interest and other income 12,450 3,129
Interest expense (29,061) (29,811)
------------- ------------
Income before income taxes 1,031,080 47,788

Benefit (provision) for income taxes 446,307 (2,635)
------------- ------------

Net income $1,477,387 $45,153
============= ============


Basic net income per share $0.42 $0.01
============= ============

Weighted average shares outstanding 3,555,870 3,400,964
============= ============

Diluted net income per share $0.36 $0.01
============= ============

Diluted weighted average shares
outstanding 4,073,315 3,512,433
============= ============


ZEVEX INTERNATIONAL INC.
CONSOLIDATED BALANCE SHEETS

March 31, Dec. 31,
2006 2005
ASSETS (unaudited)
--------------------------
Current assets
Cash and cash equivalents $926,567 $1,284,218
Designated cash for sinking fund
payment on industrial development
bond 123,126 89,037
Accounts receivable, net of allowance
for doubtful accounts of $130,000 7,806,475 5,641,229
Inventories 4,962,231 4,586,418
Marketable securities 19,350 20,250
Deferred income taxes 449,902 0
Prepaid expenses and other current
assets 216,026 193,362
------------ -------------
Total current assets 14,503,677 11,814,514

Property and equipment, net 4,890,240 4,639,136
Patents, trademarks and other
intangibles, net 341,367 348,467
Goodwill, net 4,048,264 4,048,264
------------ -------------
Total assets $23,783,548 $20,850,381
============ =============

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities
Accounts payable $3,583,287 $2,462,071
Other accrued liabilities 1,297,287 1,290,911
Deferred revenue 20,830 52,081
Current portion of industrial
development bond 100,000 100,000
Income taxes payable 6,560 2,965
Current portion of other long-term
debt 56,988 56,219
------------ -------------
Total current liabilities 5,064,952 3,964,247

Industrial development bond 1,100,000 1,100,000
Other long-term debt 695,605 710,143

Stockholders' equity
Common stock; $.001 par value,
10,000,000 authorized shares,
3,656,145 issued and 3,616,912
outstanding at March 31, 2006, and
3,566,593 issued and 3,527,360
outstanding at Dec. 31, 2005 3,656 3,567
Additional paid in capital 17,089,820 16,719,396
Unrealized loss on marketable
securities (900) -
Treasury stock, 39,233 shares
(at cost) at March 31, 2006, and
Dec. 31, 2005 (89,422) (89,422)
Accumulated deficit (80,163) (1,557,550)
------------ -------------
Total stockholders' equity 16,922,991 15,075,991
------------ -------------
Total liabilities and stockholders'
equity $23,783,548 $20,850,381
============ =============

CONFERENCE CALL

ZEVEX International Inc. invites all those interested to join the ZEVEX management team for its earnings conference call for the first quarter ended March 31, 2006. The call will be held Wednesday, April 26, 2006, at 2:30 p.m. Mountain time (4:30 p.m. Eastern, 3:30 p.m. Central and 1:30 p.m. Pacific). The telephone numbers for the call are as follows:

Domestic: 800-240-5318

International: 303-262-2141

A live webcast and a rebroadcast of the conference call will be available on the company's Web site at www.zevex.com and www.streetevents.com. To listen to the live broadcast, please enter the site 10-15 minutes prior to the call in order to download any necessary software, and then click on the "Live Webcast" link on the ZEVEX home page to access the call. The webcast will be archived on both sites. There is no other replay access to the call.

ABOUT ZEVEX

ZEVEX International Inc. (www.zevex.com), founded in 1986, is a diversified medical device company committed to creating products that transform life with patented and proprietary medical device technologies -- from sensors and surgical tools to medical electronic systems.

Forward-Looking Statements

Statements made in this press release, including those relating to anticipated growth and other statements regarding future performance, are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause actual results to differ materially from those set forth in these statements. Among other things, the company's efforts to improve its sales and margins in its core businesses may not be effective or such efforts could be more difficult or expensive than the company currently anticipates. Moreover, the company could experience delays in orders for its contract manufacturing products or in the launch of planned new products that could delay the receipt of anticipated revenue. In addition to the foregoing, the economic, competitive, governmental, technological and other factors identified in the company's filings with the Securities and Exchange Commission, including the Form 10-K for the year ended Dec. 31, 2005, may cause actual results or events to differ materially from those described in the forward-looking statements in this press release.


ZEVEX International Inc.
Phill McStotts, 801-264-1001, Ext. 203
E-mail: [e-mail]



Source: Business Wire (April 26, 2006 - 4:10 PM EDT

[Pennystock777]

ZEVEX International to Participate in the AeA Micro Cap Financial Conference May 7-9, 2006
ZEVEX International Inc. (NASDAQ: ZVXI), will participate in the AeA Micro Cap Financial Conference in Monterey, Calif., May 7-9, 2006.

On May 8, 2006, David J. McNally, president and chief executive officer, and Phillip L. McStotts, chief financial officer, will give a six-minute presentation regarding ZEVEX International's history, products, financial performance and prospects, followed by six 30-minute meetings with analysts.

About AeA

AeA (formerly the American Electronics Association), founded in 1943, is a nationwide non-profit trade association that represents all segments of the technology industry. To learn more about the Micro Cap Financial Conference, please click on the following link: www.aeanet.org/microcap.

About ZEVEX

ZEVEX International Inc. (www.zevex.com), founded in 1986, is a diversified medical device company committed to creating products that transform life with patented and proprietary medical device technologies -- from sensors and surgical tools to medical electronic systems.


ZEVEX International Inc., Salt Lake City
Phill McStotts, 801-264-1001, Ext. 203
Fax: [phone]
E-mail: [e-mail]



Source: Business Wire (April 28, 2006 - 1:41 PM EDT)

[Pennystock777]

10-Q is out and looks very Positive